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Abstract
Background: Nox-2 (also known as gp91phox), a subunit component of NADPH oxidases, generates reactive
oxygen species (ROS). Nox-dependent ROS generation and nitric oxide (NO) release by microglia have been
implicated in a variety of diseases in the central nervous system. Dexamethasone (Dex) has been shown to
suppress the ROS production, NO release and inflammatory reaction of activated microglial cells. However, the
underlying mechanisms remain unclear.
Results: The present study showed that the increased ROS production and NO release in activated BV-2 microglial
cells by LPS were associated with increased expression of Nox-2 and iNOS. Dex suppressed the upregulation of
Nox-2 and iNOS, as well as the subsequent ROS production and NO synthesis in activated BV-2 cells. This inhibition
caused by Dex appeared to be mediated by upregulation of MAPK phosphatase-1 (MKP-1), which antagonizes the
activity of mitogen-activated protein kinases (MAPKs). Dex induced-suppression of Nox-2 and -upregulation of MKP-
1 was also evident in the activated microglia from corpus callosum of postnatal rat brains. The overexpression of
MKP-1 or inhibition of MAPKs (by specific inhibitors of JNK and p38 MAPKs), were found to downregulate the
expression of Nox-2 and iNOS and thereby inhibit the synthesis of ROS and NO in activated BV-2 cells. Moreover,
Dex was unable to suppress the LPS-induced synthesis of ROS and NO in BV-2 cells transfected with MKP-1 siRNA.
On the other hand, knockdown of Nox-2 in BV-2 cells suppressed the LPS-induced ROS production and NO release.
Conclusion: In conclusion, it is suggested that downregulation of Nox-2 and overexpression of MKP-1 that
regulate ROS and NO may form the potential therapeutic strategy for the treatment of neuroinflammation in
neurodegenerative diseases.
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Background
An inflammatory process in the central nervous system
(CNS) is considered to be a prominent feature in a num-
ber of neurodegenerative diseases and is mediated by the
activated microglia, the resident immune cells of the
CNS. The microglia normally respond to neuronal
damage and remove the damaged cells by phagocytosis
[1]. The chronic activation of these cells appears to cause
neuronal damage through enhanced release of potentially
cytotoxic molecules such as proinflammatory cytokines
including tumor necrosis factor-a (TNF-a)a n d
interleukin-1b (IL-1b), nitric oxide (NO), reactive oxygen
intermediates, proteinases and complement proteins
[2-5]. Moreover, microglia-derived free radicals as well as
the reactive reaction products, hydrogen peroxide and
peroxynitrite, have the potential to harm cells and have
been implicated in contributing to oxidative damage and
neurodegeneration in neurological diseases [6,7]. There-
fore, suppression of microglia-mediated inflammation
has been considered as an important strategy in neurode-
generative disease therapy.
Nicotinamide adenine dinuceotide phosphate (NADPH)
oxidase, a multi-component enzyme complex is an impor-
tant source of reactive oxygen species (ROS) in respiratory
oxidative stress and intracellular signaling pathways [8,9].
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innate immune response by killing microbes through gen-
eration of ROS. Nox family is a subunit component of
NADPH oxidases that generate superoxide and other
downstream ROS. Among them, Nox-2 (also known as
gp91phox), is expressed in the neuron and glial cells
including microglia [10] and regulates NADPH oxidase
activities by stabilizing p22phox (also a subunit of
NADPH) to form its membrane component. Nox-depen-
dent ROS generation has been shown to regulate the pro-
duction of cytokines and chemokines as well as other
proinflammatory molecules [11,12]. Due to its expression
in microglia and ability to generate large amounts of ROS,
Nox protein is thus considered to be critical for ROS
induction in activated microglia [10].
Recent studies have demonstrated that activated micro-
glia are important sources of ROS and reactive nitrogen
species (RNS) in the brain and involved in neuroinflam-
mation processes in neurodegenerative diseases [13,14].
Abundant existence of ROS has been found to be asso-
ciated with neurodegenerative disorders such as Parkin-
son’s disease and Alzheimer’s disease [15-17]. It has also
been reported that large amount of nitric oxide (NO)
production catalyzed by inducible NO synthase (iNOS)
m a yc o n t r i b u t et oc e l l u l a rd a m a g ei nt h eC N S[ 1 8 , 1 9 ] .
Furthermore, attempts made to restrict the oxidative
stress have been proven to be of beneficial to patients
with neurodegenerative disorders. These pieces of evi-
dence indicate that limiting oxidative stress is an impor-
tant step in controlling neurodegenerative diseases.
Glucocorticoids (GC), the endogenous immunosuppres-
sors for the innate immune response and the subsequent
inflammatory reaction, have been shown to enhance the
survival of several phagocytic cells by suppressing intracel-
lular ROS production and inhibiting ROS-induced apopto-
sis [20]. Dexamethasone (Dex), a synthetic glucocorticoid,
has also been demonstrated to inhibit iNOS expression
and NO production in LPS-induced macrophages [21].
Mitogen activated protein kinase (MAPK) pathways are
important signaling cascades that mediate several cellular
functions by relaying extracellular signals to key intracellu-
lar molecules [22]. It has been previously shown that the
induction of the MAPK pathways leads to microglial acti-
vation by transcription of TNFa, Cox-2 and MCP-1
[23,24]. Three particular MAPK pathways - p38, Jun
N-terminal kinase (JNK) and extracellular signal-regulated
kinase (ERK) pathways have been shown to be regulated
by GC via activating the expression of MAPK Phospha-
tase-1 (MKP-1) [25]. We have demonstrated that Dex sup-
presses microglia-involved inflammation by inhibiting
production of monocyte chemoattractant protein-1
(MCP-1), a chemokine and subsequent migration of
microglia via MAPK phosphatase-1 (MKP-1) dependent
suppression of p38 and JNK MAPK pathways in activated
microglia [26]. However the effect of Dex on ROS produc-
tion and its possible regulatory mechanism in activated
microglia remains to be demonstrated. In this study, we
demonstrate that Dex inhibits ROS production by down-
regulating the expression of Nox-2 and by MKP-1 depen-
dent suppression of p38 and JNK MAPK pathways. These
results reveal new mechanisms by which Dex attenuates
ROS which may be helpful in developing therapeutic
strategies for minimizing oxidative stress mediated neuro-
degeneration in CNS diseases.
Results
LPS alters the ROS production and Nox-2 protein
expression in BV-2 microglial cells in a dose- and time-
dependent manner
ROS production in the BV-2 microglial cells treated with
different concentrations of LPS (0.05, 0.1 and 0.3, 1,
1.5 μg/ml) was estimated in order to choose the optimum
dose of LPS for further studies. Although the ROS produc-
tion in BV-2 cells appeared to be induced by all the con-
centrations of LPS used, a significant increase in ROS
production was observed in BV-2 cells treated with
1-1.5 μg/ml of LPS (Figure. 1A). However, the significant
increase in ROS production was found to be declined in
cells when the LPS concentration was increased to 1.5 μg/
ml. Subsequently, the BV-2 microglial cells were treated
with 1 μg/ml of LPS for different time points (2, 4, 6, 12
and 24 h). The ROS production in LPS-activated BV-2
cells was progressively increased with time, peaked at 6 h
and declined thereafter (Figure. 1B). Further, the protein
expression of Nox-2 was found to be increased maximally
in BV-2 cells treated with LPS at 1 μg/ml for 6 h (Figure.
1C). Thus we chose to treat BV-2 cells with LPS at 1 μg/
ml for 6 h for the rest of the studies.
Dexamethasone suppresses the LPS-induced Nox-2
expression in microglia in vivo and in vitro
Expression of Nox-2 was examined immunohistochemi-
cally both in vivo and in vitro. In normal and Dex treated
3d postnatal rat pups, a considerable number of lectin-
positive microglial cells were found to be distributed in
the corpus callosum of the brain, and majority of them
were colocalized with Nox-2 (Figure. 2AB). The frequency
of these cells was markedly increased in the brain of pups
which received LPS injection (Figure. 2C); however, injec-
tion of Dex decreased the incidence of these cells (Figure.
2D). In vitro, the expression of Nox-2 was greatly
increased in majority of the BV-2 cells exposed to LPS for
6 h (Figure. 2F), compared to untreated cells (Figure. 2E).
Following treatment of Dex at 0.5 μM( F i g u r e .2 G )a n d
1 μM (Figure. 2H), the Nox-2 immunoreactivity was
noticeably decreased in LPS-activated BV-2 cells. The size
of activated BV-2 cells appeared to be increased and the
size was reduced with the addition of Dex (Figure. 2E-H).
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Page 2 of 18Figure 1 A-C. Effect of LPS on the ROS production and Nox-2 protein expression in BV-2 microglial cells .F l o wc y t o m e t r yh i t o g r a m
shows that ROS production is significantly increased in BV-2 microglial cells treated with LPS at the concentration of 1.0-1.5 μg/ml for 6 h (A).
Time course analysis reveals that maximum ROS production occurs in BV-2 cells treated with LPS for 6 h (B). Western blot analysis shows that
Nox-2 protein expression is increased maximally in BV-2 cells treated with LPS at 1 μg/ml for 6 h (C). The data represent the mean ± SD (n = 3);
* p < 0.05.
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Page 3 of 18Figure 2 A-H. Confocal images showing the suppressive effect of Dex on Nox-2 expression in LPS-treated microglia in vivo and in
vitro. Colocalization of lectin (green), Nox-2 (red) and DAPI (blue) was detected in corpus callosum region of brain sections from 3d postnatal
rats with or without LPS or LPS+Dex injection (A-D). The incidence of Nox-2-positive microglial cells (arrows) was increased in the brain of LPS-
injected rats (C) compared to control (A) and to Dex alone (B)and the frequency of Nox-2-positive cells substantially decreased after Dex
treatment (D). Double labeling was also carried out between Nox-2 (green) and DAPI (blue) in BV-2 cells treated with LPS for 6 h without (F)o r
with Dex (G, 0.5 &H,1μM) in vitro. The Nox-2 immunoreactivity appears to be increased in cells treated with LPS (F), compared to control (E).
However, Dex decreased the intensity of immunoreactivity in a dose dependent manner in cells treated with LPS (G, H).
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pathways suppress the ROS production in activated BV-2
cells
The effect of Dex on ROS production in LPS-treated
BV-2 cells was examined by flow cytometry using CM-
H2DCFDA as the fluorescent probe. The fluorescence
intensity represents the amount of ROS production in
the cells. Incubation with LPS (1 μg/ml) for 6 h signifi-
cantly increased the ROS production in BV-2 cells,
when compared to that in untreated cells (Figure. 3A,B).
However, pretreatment with Dex at different concentra-
tions (0.2 μM, 0.5 μMa n d1 . 0μM), 30 min prior to
incubation with LPS prevented the increase of ROS pro-
duction significantly in BV-2 cells (Figure. 3A, B). The
inhibitory effect on ROS production in activated BV-2
cells was augmented with the increase in Dex concen-
trations. On the other hand, Dex alone at different con-
centrations did not alter ROS production in BV-2 cells
significantly, when compared with that in the control
(data not shown).
To examine whether the MAPK signaling pathways are
involved in the induction of ROS production in activated
BV-2 cells, the cells were incubated with the inhibitors of
p38 (SB203580) and JNK (SP600125) MAPKs, 30 min
prior to the addition of LPS. Flow cytometric and quanti-
tative analysis revealed that the ROS production was sig-
nificantly decreased in the LPS-stimulated BV-2 cells
exposed to either p38 or JNK inhibitors (Figure. 3C,D).
Dexamethasone and inhibitors of p38 and JNK MAPK
pathways suppress iNOS expression in microglial cells
treated with LPS
A major source of reactive nitrogen intermediates is indu-
cible nitric oxide synthase (iNOS), an enzyme expressed in
activated microglia during inflammation. Expression of
iNOS protein was hardly detectable in microglia found in
the corpus callosum of 3 day old rat brain (Figure. 4A)
and the untreated BV-2 cells in vitro (Figure. 4E). There
was marked induction of iNOS in the activated microglial
cells in vivo and BV2 cells treated with LPS (Figure. 4C,G).
The activated cells appeared to be hypertrophic and
showed abundant cytoplasm that was intensely labeled
with iNOS immunoreactivity, when compared with
untreated cells. However, Dex (1.0 μM) treatment reduced
the iNOS immunoreactivity in activated microglial and
BV2 cells (Figure. 4D,H). Dex alone did not induce the
expression of iNOS in microglial cells in vivo and BV2
cells in vitro (Figure. 4B,F).
Real time RT-PCR analysis showed that Dex (0.5 μM
and 1 μM) decreased the induction of iNOS mRNA
expression level in LPS-activated BV-2 cells (Figure. 5A,B)
in which, the iNOS mRNA level was found to be elevated
Figure 3 A-D The flow cytometric and quantitative analyses
showing the suppressive effects of Dex and inhibitors of
MAPKs on ROS production in BV-2 cells. LPS induced ROS
generation significantly in BV2 cells compared to control and
preincubation of Dex suppressed the induction of ROS production
in a dose-dependent manner (0.2, 0.5 and 1.0 μM) (A, B). Similarly,
inhibitors of p38 (SB203580) and JNK (SP600125) suppressed the
ROS generation in LPS stimulated BV-2 cells (C, D).Quantitative
analysis of ROS production in BV-2 cells subjected to different
treatments is shown in B and D. Panels A and C represent the
results of flow cytometric analysis of DCF fluorescence intensity
from one sample of each group obtained from three independent
experiments performed. The data represent the mean ± SD (n = 3);
* p < 0.05.
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cells. There was no significant change in iNOS mRNA
expression level in BV-2 cells treated with different
concentrations of Dex alone, when compared to that in
the control (data not shown). Nitrite assay revealed that
the induction of NO release in activated BV-2 cells by LPS
was attenuated significantly when the cells were exposed
to Dex together with LPS (Figure. 5C). Interestingly, real
time-RTPCR analysis showed that the iNOS mRNA
expression level was decreased by pretreatment with inhi-
bitors of p38 and JNK (SB203580 and SP600125, respec-
tively) in activated BV-2 cells, suggesting that p38 and
JNK MAPK pathways are involved in LPS-induced iNOS
expression (Figure. 5D).
Dexamethasone suppresses p38 and JNK MAPK pathways
in BV-2 microglial cells treated with LPS
It has been previously shown that Dex inhibits the LPS-
induced activation of MAP kinases in primary microglial
cultures [26]. In this study, Western blot analysis
showed that the LPS treatment at different time points
induced the phosphorylation of JNK (Figure. 6A,B) and
p38 (Figure. 6E,F) significantly in BV-2 cells. Maximum
induction was observed at 3 h after LPS treatment.
However, expression level of both phospho-p38 and
phospho-JNK declined to the basal level at 6 h after
incubation with LPS. The induction of phosphorylation
of both JNK (Figure. 6C,D) and p38 (Figure. 6G,H) in
BV-2 cells treated with LPS for 3 h was suppressed
dose-dependently by the pretreatment of the cells with
Dex.
Dexamethasone suppresses Nox-2 expression via p38 and
JNK MAPK pathways in BV-2 microglial cells treated with
LPS
Since Nox protein is considered to be critical in ROS
production in activated microglia [10], we examined if
Dex inhibits ROS production by acting on the Nox-2
expression in activated BV-2 cells. Incubation of LPS for
6 h significantly induced the Nox-2 protein expression
level in BV-2 cells when compared with untreated cells
(Figure. 7A,B). The LPS-induced Nox-2 expression was
markedly suppressed by the addition of Dex (1 μM) in
the culture and the inhibition was augmented with the
increase in Dex concentrations (Figure. 7A,B). Real time
RT-PCR results also showed that incubation of BV-2
cells with LPS for 6 h significantly induced Nox-2
mRNA expression and the increase was suppressed if
the cells were pre-incubated with Dex (Figure. 7C,D).
Next, we examined whether the inhibitory effect of Dex
on Nox-2 is mediated via MAPKs pathways. Inhibitors
of JNK and p38 showed a significant suppressive effect
on Nox-2 protein expression in activated BV-2 cells
(Figure. 7E,F). Real time RT-PCR also showed that
mRNA expression of Nox-2 was significantly suppressed
by inhibitors of JNK and p38 in LPS treated BV-2 cells
(Figure. 7G).
Knockdown of Nox-2 gene suppresses the LPS-induced
ROS generation and NO release in BV2 microglial cells
Knockdown of endogenous Nox-2 in BV-2 cells (Nox-2
siRNA) by sequence specific siRNA (Figure. 8A,B) sup-
pressed the ROS generation in control cells and prevented
Figure 4 A-H. Suppressive effect of Dex on iNOS expression in
LPS-activated microglia in the corpus callosum of 3 day old rat
brain and the BV-2 cells in vitro. Immunofluorescence analysis
shows that iNOS (red) expression, which was hardly detectable in
control cells (A, E) and cells treated with Dex alone (B, F). The
induction of iNOS immunoexpression was evident in cells exposed
to LPS (C, G). The induction was suppressed upon treatment with
Dex (D, H). Note that the cells were counterstained with DAPI
(blue). Scale bar (A-H); 50 μm.
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control and scrambled siRNA (Negative Control) treated
cells (Figure. 8C-E) and NO release (Figure. 8F).
Overexpression of MKP-1 suppresses Nox-2 mRNA
expression in BV-2 microglial cells
Since MAPKs pathways regulate Nox-2 expression and
ROS production, we examined the role of MKP-1 in the
regulation of Nox-2 by overexpressing MKP-1 in BV-2
cells. MKP-1 was localized in the microglia in the rat
corpus callosum by immuofluorescence staining (Figure.
9A-H). In brain sections of normal 3-day old and 4
weeks old postnatal rats that received saline injection
(Figure. 9A,E) or Dex injection (Figure. 9B,F), MKP-1
was hardly detectable in microglial cells distributed in
the corpus callosum. However, microglia in the brains
of rats that received LPS (Figure. 9C,G) or LPS plus Dex
injection showed marked induction of MKP-1 immunor-
eactivity (Figure. 9D,H). A similar immunoexpression
pattern of MKP-1 was observed in BV-2 cells (Figure.
10A-D). Real time RT-PCR results showed that MKP-1
mRNA expression level was significantly increased about
5 folds in LPS-treated BV-2 cells and about 2500 folds
in MKP-1- transfected (MKP-1
+) BV-2 cells when
compared to that in untreated cells (Figure. 10E,F). In
contrast, the mRNA expression level of Nox-2 was sig-
nificantly reduced in MKP-1
+ BV-2 cells compared to
that in untreated cells, and LPS treatment did not
induce Nox-2 mRNA expression level in MKP-1
+ BV-2
cells (Figure. 10G). Moreover, nitrite assay also revealed
that LPS did not induce the release of NO in MKP-1
+
BV-2 cells treated with LPS (Figure. 10H).
On the other hand, knockdown of MKP-1 (MKP-1
siRNA) with sequence specific siRNA (Figure. 11A,B) sig-
nificantly increased the ROS production (Figure. 11C,D)
and NO release (Figure. 11E) by BV-2 cells exposed to
LPS with or without Dex, in comparison to that of
controls.
Discussion
Activated microglial cells by neurodegenerative stimulus
undergo a defined pattern of physiological changes and
release a number of proinflammatory cytokines (such as
IL-1, IL-6 and TNF-a) and chemokines (MCP-1) that
contribute to neuropathogenesis in CNS inflammation
[3,26]. In addition, these cells release free radicals such
as superoxide, ROS and NO. Excessive production of
ROS and reactive nitrogen species (RNS) by activated
Figure 5 A-D. Suppressive effect of Dex and inhibitors of p38 and JNK on iNOS expression and NO release in LPS activated BV-2 cells.
iNOS mRNA (179bp) was amplified (A) and effects of Dex and inhibitors of p38 and JNK on iNOS mRNA expression were examined by the real
time RT-PCR. Both Dex (B) and inhibitors of p38 and JNK (D) decreased the induction of iNOS mRNA expression levels significantly in activated
BV-2 cells when compared with that in LPS-treated cells. Nitrite assay further shows that NO release was inhibited by Dex in LPS-induced BV-2
cells (C). The data represent the mean ± SD (n = 3)* p < 0.05, ** p < 0.01.
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Page 7 of 18Figure 6 A-H Quantitative western blot analysis showing the suppressive effect of Dex on the phospho-JNK and - p38 protein
expression in LPS treated BV-2 cells. Maximum induction of both phospho-JNK (A,B) and -p38 (E,F) protein expression was observed in
microglia exposed to LPS for 3 h. The induction of both phospho-JNK (C,D) and -p38 (G,H) protein expression in microglia was found to be
suppressed by Dex in a dose dependent manner. Panels A, C, E and G represent the Western blot of phospho-JNK and phospho-p38 protein of
each experiment with corresponding quantitative analyses of total-p38 and -JNK proteins (Panels B, D, F and H), respectively. The data represent
the mean ± SD (n = 3) * p < 0.05.
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Page 8 of 18Figure 7 A-G. Quantitative western blot and real-time RT-PCR analyses showing the suppressive effect of Dex and inhibitors of p38
and JNK on the induction of Nox-2 expression in LPS-treated BV-2 cells. Panels A and E represent the Western blot of Nox-2 protein
expression of each experiment with corresponding b-actin protein expression. Quantitative analysis of Western blot results are shown in panels B
and F. The Nox-2 mRNA (208 bp) was amplified in microglia (C). The quantitative real time RT-PCR analysis shows that Dex (D) and inhibitors of
p38 and JNK (G) suppressed the induction of Nox-2 mRNA expression in LPS-treated BV-2 cells, compared to that in cells treated with LPS. The
data represent the mean ± SD (n = 3) * p < 0.05. ** p <0.01
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Page 9 of 18Figure 8 A-F. Effect of knockdown of Nox-2 gene (Nox-2 siRNA) on the ROS production and NO release in BV-2 cells treated with LPS.
Real time RT-PCR quantitative analysis showed that about 75-80% of the endogenous Nox-2 gene expression was inhibited by its siRNA
transfection in BV-2 cells (A). Panel B shows the Nox-2 mRNA amplification curve in Nox-2 siRNA treated and untreated BV-2 cells. The flow
cytometric analysis shows that LPS did not induce ROS generation significantly in Nox-2 siRNA treated BV-2 cells compared to the LPS-treated
non-transfected cells and preincubation of BV-2 cells with Dex further suppressed the induction of ROS production (C, D). Quantitative analysis
of flow cytometric results are shown in panel D and E. Comparison between Nox-2 siRNA transfected cells and scrambled treated cells (Negative
Control) also showed that LPS was unable to induce ROS production in the cells transfected with Nox-2 siRNA (E). Nitrite assay shows that LPS
did not induce NO synthesis in Nox-2 siRNA treated BV-2 cells (F). The data represent the mean ± SD (n = 4) * p < 0.05; ** p < 0.01.
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cells (neurons and other glial cells) and is the main
cause of oxidative stress in the nervous system, leading
to neurodegenerative disorders such as Alzheimer’sd i s -
ease [15,17]. Therefore, suppression of microglia-
mediated neuroinflammation and neurotoxicity has been
considered as an important strategy in neurodegenera-
tive disease therapy. Several drugs have been shown to
alleviate symptoms of neurodegenerative diseases by
suppressing the inflammatory response of microglial
cells. However, chronic use of these drugs is often asso-
ciated with debilitating side effects, and none seems to
restrain the progression of these diseases. It is suggested
that downstream targets of these drugs may limit the
side effects of those drugs in clinical setting.
Dexamethasone, a synthetic immunosuppressor has
been shown to suppress ROS production, NO release as
well as inflammatory reaction of activated microglial
cells [20,21]. However, the mechanisms by which Dex
suppresses ROS production and NO release remained
unclear. The present study showed that the increased
ROS production and NO release in activated microglia
were associated with increased expression of Nox-2
(also known as gp91phox) and iNOS, which are the
major sources of ROS and reactive nitrogen intermedi-
ates respectively, in activated microglia. The expression
of Nox-2 has been localized in neurons and glial cells
including microglia [10] and its upregulation and subse-
quent ROS production in activated microglia were
found to be suppressed by Dex. Moreover, Dex has
been shown to provide neuroprotection by inhibiting
iNOS expression as well as NO synthesis in activated
microglia [27,28]. Hence it is suggested that Dex sup-
presses the production of ROS and NO release, and sub-
sequently neuronal oxidative damage by inhibiting the
expression of Nox-2 as well as iNOS in activated micro-
glia. The inhibition of Nox-2 by Dex observed in acti-
vated microglia appears to be mediated by MKP-1
dependent suppression of MAPKs, since the overexpres-
sion of MKP-1 and inhibition of MAPKs downregulate
the expression of Nox-2 in activated microglia.
Nox-dependent ROS generation has been shown to
induce the expression of TNF-a [12], TGF-b1, and
MCP-1 through MAP kinase activation [11] or through
transcription factors, including NFB, AP-1,and p53,
which contain redox-sensitive, low-pKa cysteine residues
in their DNA binding domain [29-31]. The Nox-depen-
dent ROS generation by microglia has also been impli-
cated in a variety of CNS diseases including stroke [32],
ischemic brain injury [33], demyelinating disease [34]
and inflammatory neurodegeneration, including Alzhei-
mer’s disease (AD) and Parkinson’s disease [35]. Hence,
suppression of NOX-dependent ROS generation may
form a better therapeutic strategy for neuroinflamma-
tion and neurodegenerative diseases.
Microglial response to extracellular stimuli is mediated
by kinase and phosphatase cascades. Several reports
have demonstrated that p38 and p44/42 families of
MAPK pathways play a significant role in activation of
Figure 9 A-H. Confocal images showing the MKP-1 expression
(red) in lectin-positive (green) microglia in corpus callosum of
3 day postnatal and in OX42 postive (green) microglia in the
corpus callosum of 4 week old rat brain subjected to different
treatments. MKP-1 immunoreactivity is hardly detectable in
microglia of control rats injected with saline (A, E) and with Dex
alone (B,F). MKP-1 immunoreactivity appears to be upregulated in
microglia distributed in the corpus callosum region of rats that
received LPS (C, G) or LPS and Dex (D, H).Scale bar (A-D), 50 μm;
Scale bar (E-H), 20 μm.
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toxic molecules and neuroinflammation in acute brain
injury such as stroke and in chronic neurodegenerative
diseases such as AD [24,36,37]. Recently, we have
demonstrated that JNK and p38 MAPKs in activated
microglia contribute to the induction of MCP-1, a che-
mokine which promotes the migration of microglia lead-
ing to amplification of the inflammation process in the
injury site [26,38]. Glucocorticoids (GC) or Dex have
been consistently shown to inhibit the expression of
Figure 10 A-H. Expression of MKP-1 in BV-2 cells and inhibition of Nox-2 expression and NO release in MKP-1-overexpressed BV-2
cells. Immunofluorescence analysis shows that MKP-1 (red) expression, which was hardly detectable in control cells (A), and cells exposed to
Dex alone (B), was induced in cells exposed to LPS for 6 h (C). The induction was further increased when the cells were pre-incubated with Dex
(D). Note that the cells were counterstained with DAPI (blue). Panel E shows that MKP-1 mRNA expression fold change is significantly increased
in BV-2 cells transfected with MKP (MKP-1
+), compared with untreated cells (control). MKP-1 mRNA amplification curves for MKP-1
+ and control
cells are shown in panel F. Furthermore, real time RT-PCR analysis and nitrite assay showed that MKP-1 overexpression significantly prevented
the increase of Nox-2 mRNA expression level (G) and NO release (H) respectively, in MKP-1
+ BV-2 cells and MKP-1
+ cells treated with LPS. The
data represent the mean ± SD (n = 3) * p < 0.05. Scale bar (A-D),5 0μm
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Page 12 of 18Figure 11 A-E. Effects of knockdown of MKP-1 gene on ROS production and NO release in BV-2 cells treated with LPS.R e a lt i m eR T -
PCR analysis showed that about 75-80% of the endogenous MKP-1 gene expression was inhibited in microglia after MKP-1 knockdown (MKP-1
siRNA) (A). Panel B shows MKP-1 mRNA amplification curves in MKP-1 siRNA treated cells and control cells. Panels C represents the results of
flow cytometric analysis of DCF fluorescence intensity from one sample of each group obtained from three independent experiments
performed. Inhibition of MKP-1 gene expression increased the ROS production in MKP-1 siRNA treated BV-2 cells as well as MKP-1 siRNA treated
cells treated with LPS or LPS+Dex, compared with untreated BV-2 cells (control) or cells transfected with negative siRNA (negative control) (C, D).
Similarly, inhibition of MKP-1 gene expression increased the NO release from LPS alone-treated cells as well as MKP-1 siRNA treated cells treated
with LPS or LPS+Dex, compared to that from negative control BV-2 cells (E). The data represent the mean ± SD (n = 4), * p < 0.05; ** p < 0.01.
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ways, in particular the p38 and JNK pathways. The inhi-
bition of MAPK pathways is mediated via induction of
MKP-1 [26,39-42]. Several proinflammatory stimuli,
such as LPS and neuromodulators such as endocannabi-
noid anandamide also induce MKP-1 expression which,
however, activates a negative feedback loop down-regu-
lating the production of pro-inflammatory cytokines,
chemokines and neurotoxic molecules such as TNF-a,
IL-1 and IL-6, MCP-1 and NO [26,39,43,44]. The induc-
tion of MKP-1 has been shown to be a survival mechan-
ism against oxidative damage in cancer cell lines [45].
Our study supports the notion that Dex inhibits JNK
and p38 phosphorylation in microglial cells by inducing
MKP-1 expression, which in turn negatively regulates
the proinflammatory response and chemotactic effect of
activated microglia [26,39].
More recently, ROS has been shown to inhibit MKP-1
activation causing activation of JNK, which contributes
to pancreatic beta-cell death [46] and to function as an
upstream regulator of JNK/SAPK and p38 MAPK [47].
On the contrary, MKP-1 activation by Dex in activated
microglia appears to limit the oxidative damage by sup-
pressing Nox-dependent ROS production. Interestingly,
overexpression and siRNA analyses of MKP-1 clearly
reveal that inhibition of Nox-dependent ROS production
by Dex in activated microglia is mediated via upregula-
tion of MKP-1, indicating a complex link between ROS
production and MKP-1 phosphorylation in activated
microglia. Moreover, this paradox could be due to the
different metabolic mechanisms in different cell types.
Conclusion
Overall, the overexpression of MKP-1 in microglia may
be considered as the possible therapeutic option as it
suppresses the ROS-mediated neurotoxicity caused by
activated microglia in neurodegenerative diseases. How-
ever, further studies involving appropriate animal mod-
els are required to determine MKP1 as the possible
therapeutic target, since the influence of other microen-




BV-2 cells (widely used murine microglial cell line) were
maintained at 75 cm
2 culture flasks in Dulbecco’sM o d i -
fied Eagle’s Medium (DMEM, Sigma, St. Louis, MO,
USA; Cat. No. 1152) supplemented with 10% fetal bovine
serum (FBS, HyClone, Logan, UT) and 1% antibiotic anti-
mycotic solution (Sigma, St. Louis, MO, USA; Cat. No.
A5955), and cultured in 37°C in a humidified atmosphere
of 5% CO2 and 95% air incubator. Cells were plated on
96-well plates at about a density of 1.0 × 10
6 per
100 mm
2 culture dish for flow cytometric assay and RNA
isolation, at 2.0 × 10
5 per well on a 24-well plate for
immunocytochemistry and at 1.0 × 10
6 per well on a
6-well plate for gene silencing MKP-1 transfection stu-
dies. On the following day after plating, cells were sub-
jected to different treatments.
Treatment of the BV-2 microglial cell culture
The dose- and time-dependent effects of LPS on ROS
production in BV-2 cells have been carried out to deter-
mine the optimal effective concentration and exposure
time of LPS. BV-2 cells were incubated in medium con-
taining LPS (Sigma-Aldrich,St. Louis, MO, USA; Cat.
NO. L2762) at various concentrations (0.05, 0.1, 0.3, 1.0
and 1.5 μg/ml) for 6 h. Subsequently, BV-2 cells were
treated with LPS at 1 μg / m lf o r2 ,4 ,6 ,1 2a n d2 4ht o
establish the time-dependent effects of LPS.
In order to study the effect of dexamethasone (Dex) on
the ROS production in LPS activated BV-2 cells, the cells
were washed with 0.1 M phosphate buffered saline (PBS),
followed by incubation in medium containing 1 μg/ml
LPS (Sigma-Aldrich,St. Louis, MO, USA; Cat. NO.
L2762) for 6 h, with or without a 30 min pre-incubation
of Dex (Sigma-Aldrich, St. Louis, MO, USA; Cat. No.
D2915) at various concentrations (0.2 μM, 0.5 μMa n d
1.0 μM). To ascertain the involvement of MAPK pathway
in ROS production and iNOS mRNA expression, BV-2
cells were incubated with either SP600125 (1 μM, A.G..
S c i e n t i f i cI n c . ,S t .D i e g o ,C A ,U S A ;C a t .N o .S 2 0 2 2 )o r
SB203580 (1 μM, Merck, Darmstadt, Germany; Cat.
No.559389), inhibitors of JNK and p38 respectively, for
30 min prior to LPS treatment for 6 h.
Measurement of ROS production in BV-2 microglia by
Flow cytometry
Intracellular ROS production was determined by detect-
ing the fluorescent intensity of 2’,7 ’-dichlorofluorescein
(DCF), the oxidized product of the fluoroprobe 5-(and
6)-chloromethyl-2’,7 ’-dichlorodihydrofluorescein diace-
tate (CM-H2DCFDA, Molecular Probers, USA; Cat. No.
C6827). Briefly, BV-2 cells grown in 100 mm
2 culture
dish at the density of 1.0 × 10
6 were treated as described
above. Subsequently, the cells were trypsinized into dis-
sociated cells and collected by centrifugation into a 15 ml
Falcon tube. The dissociated cells were re-suspended in
0.5 ml of pre-warmed PBS containing CM-H2DCFDA
(10 μmol/l) and allowed to recover for 40 min in the
darkness. After the incubation, the cells were immedi-
ately measured with a flow cytometer with excitation at
488 nm and emission at 535 nm (CyAn ADP, DakoCyto-
mation, USA) and the data obtained was analyzed with
Summit V4.2 software. The amount of ROS production
was considered to be directly proportional to the fluores-
cence intensity.
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Page 14 of 18RNA isolation and Real-time RT-PCR
Total RNA from BV2 cells was extracted with RNeasy
Mini Kit (Qiagen, Germany, Cat. No. 75161) according
to the manufacturer’s instructions and quantified spec-
trophotometrically. 2 μg of RNA from each sample was
added to a total volume of 25 μl reaction mixture con-
taining 2.5 μM of oligo (dT) primer (Promega, Madison,
WI USA; Cat. No. C110A), and 200U of Molony Murine
Leukemia Virus Reverse Transcriptase (M-MLV, Pro-
mega, Madison, WI, USA; Cat. No. M5314). The reac-
tion was initiated by incubating the reaction mixture for
1 h at 42°C for reverse transcription, and stopped by
heating for 10 min at 70°C. Aliquot (0.5 μl) of the each
reverse transcription product was added to the 20 μl
reaction mixture containing LightCycler-FastStart DNA
Master SYBR Green І,0 . 5μM of each primer corre-
sponding to mouse iNOS, Nox-2, MKP-1 or b-actin,
and 4 mM MgCl2 to amplify the genes in a LightCycler
(Roche, Germany). The primer sequences used in this
study are listed in Table 1. After pre-incubation at 95°C
for 10 min, the polymerase chain reaction (PCR) was
performed as follows: 35 cycles of denaturation at 95°C
for 15s, annealing at 60°C for 5s, and elongation at 72°C
for 12s. 2
-[ΔΔCt] method was used to compare the
mRNA expression levels of genes in experimental
groups with control groups [48].
Immunofluorescence staining in BV-2 microglial cells
BV-2 cells were plated onto poly-L-lysine coated cover
slips in 24-well plate. For immunofluorescece, the cells
subjected to different treatments were fixed with 4% paraf-
ormaldehyde at room temperature for 30 min, washed
with PBS for 30 min and blocked with 1.0% bovine serum
albumin (BSA) for 30 min. The cells were then incubated
overnight with rabbit-anti-iNOS (1:400; Chemicon, Teme-
cula, CA, USA; Cat. No. AB5382) or purified mouse anti-
gp91phox (1:500; BD Biosciences, San Jose, CA, USA; Cat.
No. 611414). Subsequently the cells were incubated with
Cy3-gonjugated goat anti-rabbit or goat anti-mouse sec-
ondary antibodies (1:200, Chemicon International, Teme-
cula, CA, USA; Cat. No. AP132C; Cat. No. AP124C),
counter-stained with DAPI and examined under a confo-
cal microscope (Fluoview 1000, Olympus, Tokyo, Japan)
Double immunofluorescence staining on postnatal rat
brain sections
Three day-old and four week-old Wistar rats were pur-
chased from the Laboratory Animal Centre, National
University of Singapore. In the handling and care of ani-
mals, the International Guiding Principles for Animals
Research, as adopted by the Institutional Animal Care
and Use Committee, National University of Singapore,
were followed. All efforts were made to minimize pain
and the number of rats used. Two injections of LPS
(1 mg/kg diluted in 250 μl of saline per injection) were
given to the pups with an interval of 6 h. 12 h after the
second injection, the pups were perfused and fixed with
4% paraformaldehyde for further procedure. In control
group, LPS injections were replaced by two injections of
saline (250 μl per injection). A single dose of Dex
(1 μmol diluted in 250 μl saline) for 3 day-old pups and
a single dose of Dex (10 μM diluted in 250 μl saline) for
4 week-old rats was given 6 h after the second injection
of LPS. Dex was allowed to function for 6 h before the
pups were sacrificed for further procedure. For double
immunofluorescence staining, rat brains were cut
through the corpus callosum. All sections were incu-
bated with purified mouse anti-gp91phox Ig (1:250; Cat
No. 611414, BD Biosciences Pharmingen, Heidelberg,
Germany) or rabbit anti-MKP-1 (1:250; Cat No. sc-1102,
Santa Cruz Biotechnology, Inc. CA, USA) or mouse
anti-iNOS (1:500, Cat No. 610431, BD Biosciences Phar-
mingen, Heidelberg, Germany) overnight at room tem-
perature. Only the tissue sections cut through the
corpus callosum of 4 weeks old rat brain were addition-
ally incubated with mouse anti-OX-42 (1:50; Cat No.
CBL1512, Millipore, MA, USA). On the following day,
the sections were further incubated with Cy3-conjugated
goat-anti-mouse secondary antibody (1:200; Chemicon,
Temecula, CA, USA) or Cy3-conjugated goat-anti-rabbit
secondary antibody (1:200; Cat No. AP132C, Chemicon)
and tomato (Lycopersicon esculentum) lectin (1:800;
Sigma-Aldrich, St. Louis, MO, USA; Cat. No. L0401) or
FITC-conjugated goat-anti-mouse IgG (1:100; Cat No.
F9137, Sigma-Aldrich Co., MO, USA) for 1 h. The
sections were counterstained with DAPI (1 μg/ml, Invi-
t r o g e n ,U S A ;C a t .N o .D 1 3 0 6 )a n dm o u n t e dw i t hf l u o r -
escent mounting medium (Dako Cytomation, Glostrop,
Denmark). Photo-images were captured using a confocal
microscope (Olympus FV1000, Tokyo, Japan).
Western blot assay
Total protein of BV-2 cells exposed to different treatments
was extracted using the Protein Extraction Kit (Thermo
Fish Scientific Inc., Rockford, IL, USA; Prod#78501) and
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Scientific Inc., Rockford, IL, USA; Prod#78410). The pro-
tein level was quantified using a protein assay kit (Bio-Rad,
Hercules, CA, USA; Cat. No.500-0007). 20 μgo fp r o t e i n
extracts were separated on 10% SDS-polyacrylamide gels
and transferred to polyvinylidene difluoride transfer mem-
branes. The membranes were blocked with 5% non-fat dry
milk and incubated with primary antibodies over night at
4°C. The primary antibodies used are as follows: rabbit
anti-phospho-JNK, total JNK, phosphor-p38 and total p38
(1:1000, all from Cell Signaling Technology, Beverly, MA,
USA; Cat. No. 9250, and 9210), gp91phox (1:1000, BD
Biosciences, San Jose, CA, USA; Cat. No. 611414) and
mouse anti-b-actin monoclonal antibody (Sigma-Aldrich,
St. Louis, MO, USA; A1978)
The next day, the membranes were incubated with the
horseradish peroxidase-conjugated secondary antibody
(Cell Signaling Technology, USA; Cat. No. 7074) for 1
h. The immunoblots were developed with the enhanced
chemiluminescence detection system. The signal inten-
sity was measured with Quantity One Software (Bio-rad,
Hercules, CA, USA) version 4.4.1.
Knockdown of Nox-2 and MKP-1 by siRNA in BV-2
microglial cells
MKP-1 and Nox-2 expression in BV-2 cells was inhibited
separately using siRNA (Silencer siRNA transfection II kit,




AACACUUCAAAAUAAGACCtc) (Refer Table 2 for all
the siRNA sequences of MKP-1 and Nox-2) and negative
control siRNA were obtained (Ambion, Inc. USA). The
siRNA transfection in BV-2 cells was performed according
to the manufacturer’s instruction. Transfection complexes
were prepared by mixing oligofectamine (Ambion,
Carlsbad CA USA, Cat. No.12252-011) and siRNAs (100
nM) in Opti-Mem Medium (Invitrogen, Life Technology,
USA). The cells were then mixed with transfection com-
plexes and incubated for 24 h in 6-well (2x10
5 cells/well).
Subsequently, the culture of both MKP-1/Nox-2 siRNA
and negative control siRNA transfected BV-2 cells were
exposed to LPS with or without Dex. The transfection effi-
ciency was assessed by quantitative real time RT-PCR
using specific primers (Table 1) for MKP-1 and Nox-2
genes.
MKP-1 overexpression in BV-2 microglia
The transfection of MKP-1 (Addgene plasmid 13469:
pWay21-MKP-1 FL) [49] into BV-2 cells was performed
using transfection reagent (LipofectamineTM 2000, Invi-
trogene, Carlsbad, CA, USA; Cat. No. 116688-027),
according to manufacturer’s instruction. BV-2 cells were
incubated in 10% FBS-DMEM without antibiotics for
24 h to reach 90-95% confluency. The plasmid (4 μg)
was mixed with 12 μl of transfection reagent and incu-
bated for 20 min at room temperature. The cells were
incubated in 2 ml OptiMEM Reduced Serum Medium
with the above transfection mixture for 6 h. Then the
cells were incubated in 10% FBS-DMEM for 24 h and
subjected for various treatments. Some cells were trans-
fected with vector backbone alone without the MKP-1
insert to assess the transfection efficiency (data not
shown).
Statistical analysis
The data were presented as mean ± SD. Statistical sig-
nificance was evaluated by either the Student’st e s to r
one-way ANOVA analysis of variance. Results were con-
sidered as significant at p < 0.05.
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